For a study, researchers sought to understand the widespread disease known as facial hyperhidrosis (HH), which has negative psychological and cosmetic effects and lowers the quality of life. There are many treatments for HH. The key goal was to identify the approach that was both safest and most successful. To assess and contrast the clinical efficacy, safety, and tolerability of topical versus intradermal administration of Botulinum toxin treatment with an injection for face HH. About 24 patients with primary facial HH were randomized into 2 equal groups at random and treated with topical glycopyrrolate gel 2% in 1 group and intradermal Botulinum toxin A injections in the other. In addition to the Hyperhidrosis Disease Severity Scale, the Dermatology Life Quality Index (DLQI), and patient satisfaction surveys, a starch iodine test was conducted both before and after treatment to gauge response. In the group receiving botulinum toxin, the action times were prolonged by up to 6 months, with 75% of patients receiving either treatment demonstrating full recovery. The consequences were mild and transient. Following treatment, there was a statistically significant improvement on the DLQI and the Hyperhidrosis Disease Severity Scale. In treating facial HH, topical glycopyrrolate 2% showed comparable outcomes to Botulinum toxin A, with a quicker onset but a shorter duration of action.
- Business of Medicine
- Doctor’s Voice